Tourmaline Bio Announces Closing of Merger with Talaris
Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular...
Piper Sandler Sandeep Kulkarni Exchange Commission Goodwin Procter Great Point Partners Talaris Therapeutics Inc
Source: globenewswire.com